was successfully added to your cart.

Large scale assessment of the mitochondrial medicine space

By | | No Comments

Need:

The management of a public pharma company needed a high level opportunity assessment of all mitochondrial disorders.

Assignment:

MSC prepared and conducted a workshop to determine the MOAs, targets and organelle components of high client relevance. An opportunity assessment was done on companies, key opinion leaders, orphan drug designations, financial deals and clinical trials to identify potential partners as well as the client’s competitive landscape. A large-scale analysis – of reviews and published studies of patient case stories and clinical trials – revealed all molecules previously tested in various mitochondrial disorders together with their clinical results. The company management have subsequently implemented the content of the detailed dossier and executive summary presentation into its business plan and used the delivery in various discussions with partners and investors.

Company repositioning and development of new investment case

By | | No Comments

Need:

The CEO of a clinical phase 2 company needed to reposition the company’s existing business communication for development in a new indication.

Assignment:

MSC led a number of workshops to determine the new strategic direction of the company together with the company management. An extensive communication strategy was developed to communicate the new target product profile along with a new scientific MOA rationale. MSC established an investment presentation, tailoring it to fit in with the new strategy, upgraded the presentation’s graphical design and visual appearance, and crafted a credible storyline to use along with the investment presentation. Based on the main document, a series of confidential and non-confidential work packages as well as conference partnering folders were developed and delivered, which allowed the CEO and management to spend more time preparing for and initiating investor interactions.